Turkish Journal of Medical Sciences
Volume 51

Number 5

Article 1

1-1-2021

Allergic reactions against Covıd-19 vaccines
HİLAL ÜNSAL
BÜLENT ENİS ŞEKEREL
ÜMİT MURAT ŞAHİNER

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ÜNSAL, HİLAL; ŞEKEREL, BÜLENT ENİS; and ŞAHİNER, ÜMİT MURAT (2021) "Allergic reactions against
Covıd-19 vaccines," Turkish Journal of Medical Sciences: Vol. 51: No. 5, Article 1. https://doi.org/10.3906/
sag-2104-329
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss5/1

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2021) 51: 2233-2242
© TÜBİTAK
doi:10.3906/sag-2104-329

http://journals.tubitak.gov.tr/medical/

Review Article

Allergic reactions against Covıd-19 vaccines
Hilal ÜNSAL, Bülent Enis ŞEKEREL, Ümit Murat ŞAHİNER
Department of Pediatric Allergy, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Received: 26.04.2021

Accepted/Published Online: 31.07.2021

Final Version: 21.10.2021

Abstract: Coronavirus Disease 2019 (COVID-19) affected the whole world in a short time. One of the most influential public health
initiatives modern medicine has to offer, the vaccine has become even more important as the COVID-19 pandemic continues to worsen
worldwide. Many vaccine trials were launched during the COVID-19 pandemic, and these vaccines were widely used around the world,
offering realistic hope for ending the pandemic. Allergic reactions to vaccines were reported shortly after their approval. These reactions,
in general, are rare, but, in some circumstances, they can be serious. Allergy to vaccines can occur because of either the active vaccine
component or vaccine ingredients. The spectrum of the reactions may be just a local hypersensitiviy reaction or may be as severe as
an anaphylaxis, which is an acute severe, life-threatening systemic hypersensitive reaction, and it requires quick intervention. If an
allergy is suspected, a correct examination followed by algorithms is important for true diagnosis, treatment, and decision regarding
revaccination. Patients who experience an allergic reaction with the first dose of covid 19 vaccine should be directed to the allergyimmunologist, and the evaluation of at-risk patients should be individualized. Finally, we should point out that the benefits of current
COVID-19 vaccines go far beyond the side effects, and that the vaccine is the most important way to recover from the pandemic.
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1. Introduction
Routine immunization has effectively reduced death and
morbidity rates because of a variety of infectious diseases,
and it is one of the most effective public health interventions
[1,2]. Severe allergic reactions to vaccines are rare and difficult
to predict. In general, anaphylactic reactions to vaccinations
occur at a rate of about 1 per million.[3, 4] Vaccination has
become increasingly important as the global pandemic,
the 2019 coronavirus disease (COVID-19), continues to
worsen worldwide. After the COVID-19 pandemic, many
vaccine studies began worldwide, and vaccines such as
Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and
AstraZeneca recombinant ChAdOx1-S were first approved.
Although rare, severe allergic reactions to mRNA-based
vaccines were reported shortly after their approval.[4] In this
review, we aimed to make an allergic reaction risk assessment
related to COVID-19 vaccination and recommend a standard
diagnostic and management procedure in case of reaction.
2. Covid-19 vaccines and allergic reactions
RNA vaccines, inactivated vaccines, replication-incompetent
vector vaccines, and recombinant protein vaccines are

different vaccine approaches produced for protection from
covid 19 infection. BNT162b2 (Pfizer-BioNTech) and
mRNA-1273 (Moderna) are mRNA vaccines, and they are
delivered in a lipid nanoparticle to express a full-length
spike protein. Since the approval of mRNA-based vaccines,
severe general reactions have been reported from the
United Kingdom and the United States. Twenty-one adverse
events were detected as anaphylaxis after administration
of a reported 1,893,360 first doses of the Pfizer-BioNTech
COVID-19 vaccine (11.1 cases per million doses) [5, 6].
Anaphylaxis has also been reported from the Moderna
mRNA COVID-19 vaccine.[7] This has triggered the need
to provide recommendations on how to manage covid 19
vaccine allergic reactions.
The AstraZeneca ChAdOx1-S (Vaxzevria) vaccine,
which is a recombinant chimpanzee adenoviral vector,
and the Johnson & Johnson Ad26.COV2.S (Janssen)
vaccine, which is a recombinant adenovirus type 26
vector, were other produced vaccines on the market.1-2
Approximately 6.85 million doses of Johnson & Johnson
COVID-19 vaccine (Janssen) have been administered in
the USA. Six cases of cerebral venous sinus thrombosis
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with thrombocytopenia have been reported after receiving
Janssen COVID-19 vaccine. All of the cases consisted of
women between the ages of 18–48, and the events occurred
6-13 days after vaccination. One patient has died. In the
statement made by the FDA and the Centers for Disease
Control and Prevention (CDC), it was recommended
to stop the use of Janssen COVID-19 vaccine and the
USA, South Africa, and the European Union decided to
temporarily stop the use.3
Unusual cases of thrombotic complications along with
thrombocytopenia have been observed in patients after
vaccination with AstraZeneca ChAdOx1-S (Vaxzevria).
The majority of these reported cases occurred within
2 weeks after vaccination and consisted of women
under 60 years of age. The safety committee of EMA
(Pharmacovigilance Risk Assessment Committee, PRAC)
has comprehensively reviewed 62 cases of cerebral
venous sinus thrombosis and 24 cases of splanchnic vein
thrombosis, 18 of which were fatal. The EMA declared
that, based on the currently available evidence, certain
risk factors cannot be confirmed, unusual thrombotic
complications with low platelets should be listed as very
rare side effects of Vaxzevria,and concluded that the
benefits of the vaccine continue to outweigh the risks for
those receiving the vaccine.4 The British Medicines and
Healthcare Products Regulatory Agency (MHRA) stated
that the benefits of vaccination for people aged 30 and
over and those with other health problems outweigh the
risk of coagulation problems and for people under the
age of 30 who do not have other health problems, it is
currently recommended that another COVID-19 vaccine
be preferred over the AstraZeneca vaccine.5
3. Mechanisms of hypersensitivity reactions for vaccines
An allergic reaction is defined as a harmful idiosyncratic
response given by an immune mechanism.[8] Allergic
reactions caused by vaccines are usually of Type I and
IV hypersensitivity reactions. Immunologically mediated
allergic reactions are either acute in onset or delayed.
[9] The majority of acute-onset reactions are type I
hypersensitivity reactions.[10] Immediate reactions to
vaccines is caused by the presence of IgE in a patient,
which can precipitate degranulation of mast cells (MC)
and release of histamine in reply to an antigen within the
vaccine.[11]

Mast cells are thought to play a major role in the
development of immediate allergic reactions, and, as upon
activation, they release a kind of mediators from stored
granules. Also mast cells are involved in homeostasis,
inflammation, innate and adaptive immunity, angiogenesis
in various tissues.[12] Therefore, they are often found at the
host-environment interface, like the skin, gastrointestinal
tract or lungs which are threatened by various external
factors, pathogens and allergens. Main receptor systems and
ligands involved in mast cell activation are shown in Figure
1.[13] Postactivation MCs release numerous mediators in
immediate reaction. Histamine, proteases, heparin and
prostaglandin D2, leukotriene C4, thromboxane, tumor
necrosis factor alpha, etc. are among these mediators.[14]
4. Clinical manifestations
4.1. Immediate allergic reactions
Immediate hypersensitivity to vaccines is rare; however, it
is important for the clinician to recognize these reactions
correctly for the future vaccine administration decision. It
has been stated that the average rate for immediate type
reactions in children and adolescents is 0.22 per 100,000
doses of vaccinations.[15] Allergic hipersensitivite
reactions to vaccines may be mild and limited in the scope
of symptoms and involvement of organ systems. The most
common symptoms of IgE-mediated allergic reactions are
urticaria and angioedema, with less common symptoms
including nasal congestion, wheezing, cough, stridor,
vomiting, diarrhea abdominal pain and hypotension.
Thus, typical signs of an allergic reaction occurring an
onset within minutes and less than 4 h postvaccination.
[16–18]
4.2. Anaphylaxis
Anaphylaxis is an acute severe, life-threatening
generalized or systemic hypersensitive reaction.[19–21]
Anaphylaxis is triggered by the binding of an allergen
to specific immunoglubulin E (IgE). Anaphylaxis to
vaccines is rare. The incidence of anaphylaxis with
vaccine estimated at 1.31 in 1 million doses given.[3]
Anaphylaxis is a rapidly progressive allergic reaction
involving multiple organ systems such as skin, respiratory,
circulatory and gastrointestinal systems. Although skin
findings are the most common, skin findings may not
be seen in anaphylaxis.[22–24] Symptoms of anaphylaxis
generally have their onset within minutes and symptoms
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Figure 1. The structure of the mast cell: main receptor systems and ligands.[13]

usually start within the first hour after immunization.
[17] The faster the anaphylaxis begins, the more severe
the reaction. Although uniphasic reactions are mostly
seen, 20% biphasic reaction can be seen.[25] Vaso vagal
reactions may occur after vaccination and can be confused
with anaphylaxis.[26] Bradycardia, vasodilatation and
hypotension occur and pallor, nausea, vomiting, profuse
sweating, myoclonus and/or incontinence such symptoms
can be seen. Hypotension may occur in both vasovagal
reactions and anaphylaxis. Absence of bronchospasm
and particularly cutaneous manifestations in vasovagal
reactions is important in differential diagnosis. Heart rate
is usually high in anaphylaxis, but bradycardia is always
seen in vasovagal reactions.[25, 27] In the patient group
with a history of vasovagal reaction, future vaccines should
be administered while lying supine.[26]
4.3. Delayed reactions
Delayed type reactions can be seen generally days after
exposure, but the onset of symptoms can be as early as 6
hours or delayed for up to 2 to 3 weeks. These reactions
may be nonimmunologic or immunologic. Maculopapular
rash on the skin is the most common symptom of delayedtype reactions.[11, 28] Aluminum containing vaccines
may cause an injection site nodule, this may be involved to
delayed type hypersensitivity to aluminum.[29]
4.4. Local reactions
Local reactions include pain, redness, and/or swelling
at injection site are common and selflimited. Large local
reactions are less common and generally occur within
24–72 h after administration.[30] Mild local reactions
are seen due to nonspecific inflammation both from the

vaccine injection itself and from the injection of foreign
substances. Therefore, the administration technique is
important. Deeper injection application and injection in
the thigh rather than the arm are associated with a lower
incidence of local reactions.[30–32] Local reactions and
constitutional symptoms, especially fever, are common
after the administration of many vaccines and do not
contraindicate administration of future doses of the same
vaccine.[33,34]
5. What are the possible causes of Covid 19 vaccine
reactions?
Vaccines include not only the antigen in charge of
stimulating the immune response, but they also contain
a number of additional ingredients. Therefore, an allergic
reaction occurs not only against the active ingredient
itself but also against the vaccine components. Covid 19
vaccines and their ingredients are shown in the Table 1.
[35]. To date, allergic reactions mostly related to covid-19
vaccines have been attributed to two important ingredients,
polyethylene glycol and polysorbate 80.
5.1. Polyethylene glycol (PEG)
Allergic reactions to vaccines are often due to additives,
preservatives and other ingredients rather than the active
ingredient itself.[10, 35] Pfizer-BioNTech and Moderna
Covid-19 mRNA vaccines are not formulated with any
drugs, food or latex. Both vaccines contain, in addition
to the modified viral mRNA, various salts, carbohydrates
and lipids and the excipient PEG (Polyethylene glycol).
[36, 37] At present, there are no other vaccines that use
PEG 2000. PEG, also known as macrogol, is an excipient
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Table 1. Covid 19 vaccines and their ingredients [35].
Vaccine

Manufacturer

BNT162b2

§ [(4-hydroxybutyl)azanediyl) bis (hexane-6,1- diyl)bis(2-hexyldecanoate)]
§ 2[(PEG)-2000]-N,N ditetradecylacetamide
§1,2-Distearoyl-sn-glycero-3-phosphocholine
§Cholesterol
Pfizer-BioNTech mRNA-based vaccine
§Potassium chloride, monobasic potassium phosphate, sodium chloride,
dibasic sodium phosphate dehydrate
§Sucrose
§ Water for injections

mRNA-1273 Moderna

ChAdOx1

CoronaVac

AstraZeneca

Sinovac

Vaccine type

Ingredients

§SM-102, 1,2-dimyristoylrac-glycero-3- methoxypolyethylene glycol-2000
[PEG2000-DMG
§1,2-Distearoyl-sn-glycero-3-phosphocholine
mRNA-based vaccine
§Cholesterol
§Tromethamin, Tromethamin hydrocholoride, acetid acid, sodium acetate
§Sucrose
Vector-based vaccine
Replicationİncompetent
Chimpanzee
Adenovirüs vectör

Inactivated SARS
CoV-2 virus

§L-Histidine
§L-Histidine hydrochloride monohydrate
§Polysorbate 80
§Magnesium chloride hexahydrate
§Sodium chloride
§Disodium edetate dihydrate
§Ethanol
§Sucrose
§ Water for injections
§Disodium hydrogen phosphate
§Sodium dihydrogen phosphate
§Sodium chloride
§Aluminum hydroxide

for the purpose of stabilizing the lipid nanoparticle
containing the mRNA. PEG is widely used in many daily
products including; cosmetics, drugs, lozenges, laxatives,
food additives and rarely trigger hypersensitiv allergic
reactions.[38–44] IgE-mediated hypersensitiv reactions
and anaphylaxis have been reported to PEGs of different
molecular weights and the majority of reactions are due
to high molecular weight PEGs.[40, 42] Otherwise, PEG
can trigger non-IgE dependent complement mediated
mast cell activation through IgG or IgM. This situation is
called “Complement Activation-Related Pseudoallergy”
(CARPA), which is caused by the activation of the
complement system. These hypersensitivity reactions occur
directly upon first exposure to lipid excipients, including
lipid nanoparticles without prior sensitization, and the
symptoms generally decrease or disappear on subsequent
treatment. Thus, such immunological responses are called
‘pseudoallergy’. [37, 45, 46]
5.2. Polysorbate 80
The AstraZeneca recombinant adenoviral ChAdOx1-S
vaccine contain the excipient polysorbate 80. Polysorbate
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80, also known as Tween 80. Polysorbate, structurally
similar to PEG. Polysorbate is also an excipient in a many
medical products (eg, vaccines, vitamin oils, anticancer
agents), ointments, lotions, creams, and medication
tablets. [36, 47] At least 70% of injectable biological agents
and mAb treatments include a polysorbate. Most typically
there is polysorbate 80. [48] Polysorbate 80 has been used
as excipient in numerous vaccines (e.g., influenza vaccines,
pneumococcal conjugate vaccine, DTaP and its analogs,
HepB, HPV, zoster). [35] Polysorbate can crossreact
with PEG and may cause IgE-mediated hypersensitivity
reactions. [49]
5.3. Patient Related risks and Covid-19 Vaccine Allergy
A history of food, venom, inhalant, latex, pet allergies
and allergy to oral medications (including the oral
equivalent of an injectable medication) are particularly
listed as not being precautions or contraindications for
receiving the covid 19 vaccine. In case of mastocytosis/
mast cell activation syndromes, idiopathic anaphylaxis,
severe or multiple drug allergy and previous anaphylaxis
to other vaccines, patients should be referred to an
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Table 2. Allergic risk assessment for COVID-19 vaccination and suggestions during vaccination[35]-⁶.
The Patients’ History

Suggestions

Proceed with vaccination

Food allergy
Allergic asthma
Allergic rhinoconjunctivits
Atopic eczema
Urticaria
Insect venom allergy
Allergy with oral medications
Family history of allergies
Local reaction history with previous
vaccination

Vaccination with precautions

History with immediate allergic
reactions(mostly anaphylaxis) to other
vaccines or injectable medication
History of idiopathic anaphylaxis
Mast cell disorders

Vaccination is contraindicated

History of allergic reactions to prior dose
vaccine or the vaccine ingredients

allergist before vaccination, but these are not considered
contraindications. These patients are considered to be
observed for 30 min after vaccination, and vaccination
in a hospital setting is recommended. (Table 2) [35]-6
These vaccines are contraindicated in case of allergy to
one of the components of the vaccine and in case of severe
allergic reaction to the first dose.[35, 50]-⁶ Although no
severe reaction to vaccines have been noticed, a strong
relationship has been observed between anaphylaxis and
asthma, particularly when asthma is not well-controlled.
[51] If there is uncontrolled asthma, vaccination is
recommended in a hospital setting. If patients are allergic
to latex, vaccination is done only with latex-free gloves.
[50] Patients with only a delayed onset local reaction
around the injection site after the first vaccine dose do not
have a contraindication or precaution to the future dose.⁶
6. Management of severe hypersensitivity reactions and
anaphylaxis
Anaphylaxis is considered a medical emergency with its
immediate onset and rapid progression to cardiovascular
and/or respiratory collapse resulting in death within
minutes of inception. Therefore, it requires quick
intervention. The first thing to do is to quickly evaluate the
patient’s circulation, respiration, consciousness and skin
findings and to give the appropriate position. Adrenaline

Routine vaccination with 15 minute observation
[Observation time can be extended up to
30 minutes (e.g. in patients with a history of
anaphylaxis)]

-Referral to the allergy centre
-longer observation (30 minute) and monitoring
of vital signs if vaccination is to be applied

-Do not vaccine administration
-Referral to the allergy centre
(evaluate potential alternative Covid-19
vaccination)

should be administered immediately in patients with a
diagnosis of anaphylaxis or with a high probability. It
should be known that delayed adrenaline therapy may
cause the reaction to progress rapidly and result in death.
Adrenaline administered intramuscularly (in a dose of
0.01 mg/kg of a 1:1000 [1 mg/mL] solution to a maximum
of 0.5 mg in adults and 0.3 mg in children). Adrenaline
should be administered intramuscularly (IM) to the
middle anterolateral part of the thigh (vastus lateralis
muscle).[21, 22, 52] Depending on the clinical condition
of the patient, the dose can be repeated every 5–15 min.
The patient should lie on her/his back and legs up. The
patient’s blood pressure, heart rate, O2 saturation should be
measured periodically, and respiratory and cardiac status
should be evaluated.
If hypotension persists or signs of cardiovascular
shock occur despite IM given adrenaline, rapid IV fluid
(saline) replacement is required. Crystalloids are the fluid
of choice and should be given in boluses of 20 mL/kg.
[19, 53] Patients with respiratory distress should be given
high flow oxygen (preferably 100% using a nonrebreather
facemask).[54] In the presence of shortness of breath and
wheezing despite the injection of adrenaline, inhaled beta
2 agonists can be applied.[19, 55] Antihistamines are
effective on skin, nasal, and eye symptoms. However, they
do not prevent the development of airway obstruction,

United States Centers for Disease Control and Prevention (2020) .Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently
Authorized in the United States [online]. Website https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. [Reviewed
December 20, 2020].
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hypotension, and shock. Therefore, they should not
replace adrenaline.[56] The role of corticosteroids in the
treatment of anaphylaxis is controversial. However, it has
not been shown that corticosteroids reduce the severity of
the reaction or prevent premature death in anaphylaxis.
It should never be administered before adrenaline, and
it should be known that it will not replace adrenaline in
anaphylaxis.[56–58] Glucagon should be administered
in cases where anaphylaxis develops while using beta
blockers, if hypotension persists despite adrenaline
administration. A total of 1–5 mg in adults and 20–30 mg/
kg (maximum 1mg) in children should be IV administered
over 5 min. Then 5–15 mg/dk IV infusion is continued.[19,
59] The algorythm of diagnosis and treatment for covid 19
vaccines related reactions is shown in Figure 2. [19, 50]
All patients with anaphylaxis should be observed
until symptoms have completely resolved. Patients
who presented with respiratory failure should be with
care monitored for at least 6–8 hour, and patients who
presented with hypotension require monitoring for at least
12–24 h.[19] Patients with a severe initial presentation or
the need for more than one dose of epinephrine may be
at increased risk for recurrent symptoms so an extended
observation period of 24 h is recommended for patients.

[50, 52] In the case of a severe anaphylactic reaction, the
risk of biphasic anaphylaxis increases. Risk factors for the
occurrence of biphasic anaphylaxis can be summarized
as needing repeated doses of epinephrine (ie >1 dose of
epinephrine), unknown trigger of anaphylaxis, large pulse
pressure, drug-induced anaphylaxis in children, and
cutaneous signs and symptoms.[52] On discharge, patients
should be instructed to see an allergist immunologist for
the future vaccination decision.
7. Follow up and diagnostic procedures
7.1.The management of patients who experience
potentially allergic reactions to a COVID-19 vaccine
Patients who experience an allergic reaction with the first
dose of covid 19 vaccine should be directed to the allergyimmunologist for the next dose of vaccine approach. The
evaluation of at-risk patients should be individualized.
Patients with a previous history of anaphylaxis against a
vaccine should be revaccinated only if absolutely necessary.
[30] A split-dose challenges protocol could provide an
option for administration in people at higher risk for
developing serious or fatal COVID-19 infections and
who have already experienced a suspected or confirmed
severe allergic reaction to a COVID-19 vaccine or any of

Figure 2. An algorythm of diagnosis and treatment for covid 19 vaccines-related reactions [19, 50].
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Table 3. Recommendations for covid 19 vaccines.
Recommendations for covid 19 vaccines
Anaphylaxis is a severe, life-threatening allergic reaction that occurs rarely following vaccination.
Locations administering Covid-19 vaccines should have necessary supplies and staff members available to manage anaphylaxis
and immediately treat suspected anaphylaxis with intramuscular adrenaline injection.
A history of food, venom, inhalant, latex, pet allergies, and allergy to oral medications (including the oral equivalent of an
injectable medication) are not contraindications for receiving the covid 19 vaccines.
Mastocytosis/mast cell activation syndromes, idiopathic anaphylaxis, severe or multiple drug allergy and previous anaphylaxis
to other vaccines are not considered contraindications for vaccination. These patients are recommended to be observed for 30
min after vaccination in a hospital setting.
Patients with only a delayed onset local reaction around the injection site area after the first vaccine dose do not have a
contraindication for the future dose
In case of postvaccination allergic reaction, the patient should be referred to an allergy immunologist.
An allergic reaction occurs not only against the active ingredient itself but also against the vaccine components.
Skin prick tests should be performed by allergy-immunologists evaluating the benefits and risks in an appropriate settings.

its components. For other vaccines split-dose challenges
(administer 0.05 mL of 1:10 dilution, and 10%, 20%, 30%,
and 40% of the full dose incrementally in alternate arms
at 15-min intervals, followed by a minimum 30-minute
observation period) have been used.[5, 17] That it is
typically performed with other vaccines, but, currently,
there are no supportive efficacy or safety data for this
approach.
As a different approach, patients with negative skin
tests to the vaccine but with a history of anaphylaxis or
severe allergic reactions can be immunized with splitdose vaccination. At first, 10% of the dose is administred,
and 30 min later, the remaining 90% is applied provided
that no allergic reaction has occurred following the initial
dose. These vaccination approaches should only be used
by experienced personnel in a controlled settings where
emergency treatment of anaphylaxis is available [30].
Patients who have experienced a systemic allergic
reaction to vaccine should not receive a second dose
of that vaccine, nor a vaccine with similar ingredients.
European Medicines Agency (EMA) and U.S. Food and
Drug Administration (FDA) recommended the vaccine
should not be administered if there is an allergy to one of
the components of the vaccine and if there was a severe
allergic reaction to the first dose. Vaccination should
be administered under close medical supervision with
appropriate medical attention.[50]-7For people who have
a contraindication to one type of COVID-19 vaccine that
is currently permitted, care should be taken to apply other
vaccines. For example, patients with a contraindication to
one of the mRNA Covid-19 vaccines should not receive

doses of either of the mRNA vaccines. Both mRNA
Covid-19 vaccines contain polyethylene glycol (PEG), and
the AstraZeneca-ChAdOx1-S Covid-19 vaccine contain
polysorbate 80. Cross-reactive hypersensitivity may occur
between PEG and polysorbate, but after appropriate
precautions have been taken, in case of a contraindication
to mRNA COVID-19 vaccines, people may be able to
receive Janssen COVID-19 vaccine, and vice versa.⁶ If
there is no other contraindication (for example; a proven
allergy to polysorbate 80), the UK recommendation is that
the AstraZeneca vaccine can be used as an alternative.[35].
7.2. Diagnostic procedures
Allergological study include detailed history and in vitro
tests with the vaccines and their components. The sensitivity
and specificity of skin tests with vaccines in confirming or
discarding allergy to a vaccine or its ingredients have not
been established.[8] But, if skin testing results negative,
it is very unlikely for the patient to have IgE against the
vaccine or its ingredients. If the suspected vaccine contains
specific components known to be potentially allergenic,
testing should also be conducted for those components.
A prick test can be performed with the culprit vaccine
solution as well as with PEG and polysorbate (titrated 10%
and 1%). Currently the limited covid 19 vaccine supply,
lack of information about sensitivity or specificity, and
uncertain safety of the skin testing can interfere with skin
testing with the vaccine.
PEG and polysorbate skin testing may be of value in
decision making around future COVID-19 vaccination.
PEG 3350 is available as a laxative (miralax and others)
for prick skin testing, and Refresh Optive Advanced

European Medicines Agency (2020). EMA/660602/2020; EMEA/H/C/005735 [online]. Website https://www.ema.europa.eu/en/news/emarecommends-first-covid-19-vaccine-authorisation-eu. [21.12.2020].
7
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Lubricant eye drops and Prevnar are an alternate source
for polysorbate 80 skin testing.[36] Concentrations as high
as 100% (17 g/17 mL) have stated to be nonirritating for
prick skin testing.[40, 42] If the PEG prick skin test result
is negative, an intradermal test can be performed; at first
with a 1:100 dilution and, if negative, at a 1:10 dilution.
It is still unknown whether a negative prick test
has sufficient positive or negative predictive power to
determine the risk of a serious systemic reaction. Systemic
reactions, including anaphylaxis, have been associated
with both skin prick testing and intradermal testing.[36,
38] So these tests should be performed with evaluating
the benefits and risks by experts in an appropriate settings.
(Table 3)

patients understand the overall benefit of vaccination
against SARS-CoV-2, and they should be aware that an
extremely low overall risk of allergic reactions is related.
As allergists, we must be clear and evidence-based
about allergic reaction risks with these vaccines. In near
future, molecular diagnostic methods may also be used,
and desensitisation protocols with vaccine or vaccine
components can be applicable. The most important thing
to keep in mind is that the benefits of the vaccine go far
beyond the side effects, and most vaccine-related side
effects are mild allergic reactions.

8. Conclusion
Covid 19 virus has killed millions worldwide; however,
only a very small number of patients have suffered from
reactions after vaccination. It is very important that
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